Semaglutide

Semaglutide is a peptide medicine. It is a modified version of GLP-1, a naturally occurring hormone released by the gut after eating.

Researchers changed the molecule in two important ways. A fatty-acid side chain helps it bind to albumin, a protein in the blood. Other substitutions make it more resistant to breakdown by the enzyme DPP-4. Together, these changes extend its half-life to about one week and allow once-weekly dosing (Lau et al., J Med Chem, 2015 PMID 26308095).

The same molecule is sold under different brand names for different approved uses:

• Ozempic: once-weekly injection for type 2 diabetes (FDA: December 5, 2017; Health Canada: January 4, 2018).
• Rybelsus: once-daily oral tablet for type 2 diabetes (FDA: September 20, 2019). It uses an absorption enhancer (SNAC) to survive the stomach. It is not the same formulation or dose as the injectable.
• Wegovy: once-weekly injection at a higher dose (2.4 mg) for chronic weight management (FDA: June 4, 2021) and, since March 8, 2024, to reduce cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and overweight or obesity.

A brand name and a molecule are not the same thing.

A branded approval applies to a specific product, formulation, dose, indication, and country. It does not establish approval for research-use powders, compounded copies, or other products merely containing or claiming a similar name.

The FDA has issued warnings about unapproved products marketed as GLP-1 drugs for weight loss (FDA).

Researchers are studying semaglutide because the GLP-1 pathway connects several metabolic processes, including blood-sugar control, appetite, body weight, and, increasingly clear from trials, cardiovascular and kidney risk.

The main research questions have been:

• Does it improve glycemic control, measured by HbA1c, in type 2 diabetes, and how does it compare with existing medicines?
• Does it produce clinically meaningful, sustained weight loss in adults with overweight or obesity?
• Does it reduce major adverse cardiovascular events, meaning heart attack, stroke, or cardiovascular death, in people with type 2 diabetes and in people with obesity but no diabetes?
• Does it slow kidney disease progression in type 2 diabetes?
• Does it improve symptoms and function in obesity-related heart failure?
• Can an oral formulation achieve comparable effects to the injection?

Semaglutide has one of the largest human-trial literatures of any peptide medicine. The major programs have examined blood sugar, body weight, cardiovascular outcomes, kidney disease, heart failure, and oral formulations.

Blood sugar in type 2 diabetes. The SUSTAIN program tested once-weekly injectable semaglutide (0.5–2.0 mg) in type 2 diabetes. The PIONEER program tested the daily oral tablet (3, 7, 14 mg).

In PIONEER 1, 703 adults were followed for 26 weeks. Oral semaglutide lowered HbA1c, the standard blood marker of average blood sugar, by up to 1.1 percentage points more than placebo at the 14 mg dose. Participants also had modest weight loss, 2.3 kg more than placebo. PMID 31186300.

Certainty: Moderate · Provisional. Randomized, placebo-controlled evidence, but short duration and a single trial for this comparison.

Cardiovascular outcomes in type 2 diabetes. SUSTAIN 6 randomized 3,297 adults with type 2 diabetes at high cardiovascular risk to once-weekly semaglutide or placebo for 104 weeks.

The primary outcome was a composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke, often called MACE. It occurred in 6.6% of participants receiving semaglutide versus 8.9% receiving placebo (hazard ratio 0.74; 95% confidence interval 0.58–0.95). The trial confirmed noninferiority with a suggestion of superiority (P=0.02 for superiority). PMID 27633186.

Certainty: Moderate · Provisional. Large randomized trial, but designed for noninferiority and relatively short for cardiovascular outcomes.

Weight loss in adults with overweight or obesity without diabetes. STEP 1 randomized 1,961 adults with BMI ≥30, or ≥27 with a weight-related condition, to semaglutide 2.4 mg weekly or placebo for 68 weeks. Both groups received lifestyle intervention.

Mean weight change was −14.9% with semaglutide versus −2.4% with placebo, an estimated treatment difference of −12.4 percentage points. At least 5% of body weight was lost by 86.4% versus 31.5% of participants. At least 15% was lost by 50.5% versus 4.9%. PMID 33567185.

STEP 5 extended the question to 104 weeks in 304 adults: −15.2% versus −2.6%. PMID 36216945.

An oral 50 mg daily formulation in OASIS 1 produced −15.1% versus −2.4% at 68 weeks. PMID 37385278.

Certainty: High · Provisional. Large, consistent randomized evidence.

Cardiovascular outcomes in obesity without diabetes. SELECT randomized 17,604 adults aged ≥45 with overweight or obesity and established cardiovascular disease, but no diabetes, to semaglutide 2.4 mg weekly or placebo. Mean follow-up was 39.8 months.

The MACE composite occurred in 6.5% versus 8.0% (HR 0.80; 95% CI 0.72–0.90; P<0.001). Mean weight fell 10.2% versus 1.5% at 208 weeks.

A prespecified analysis found that the cardiovascular benefit was largely independent of the amount of weight lost. PMID 37952131.

Certainty: High · Provisional. Very large randomized trial with hard clinical outcomes.

Kidney disease in type 2 diabetes. The FLOW trial randomized adults with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg weekly or placebo.

The trial was stopped early after an interim analysis favored semaglutide on the primary composite of major kidney disease events: kidney failure, ≥50% eGFR decline, or kidney/cardiovascular death. PMID 38785209.

Certainty: Moderate · Provisional. Randomized trial. Early stopping can exaggerate effect estimates.

Heart failure with preserved ejection fraction (HFpEF) and obesity. STEP-HFpEF randomized adults with obesity and HFpEF to semaglutide 2.4 mg weekly or placebo for 52 weeks.

Heart-failure symptoms and physical limitations, measured with the Kansas City Cardiomyopathy Questionnaire clinical summary score, improved by 16.6 versus 8.7 points (difference 95% CI 4.8–10.9; P<0.001). Body weight fell 13.3% versus 2.6%. Six-minute walk distance increased 21.5 m versus 1.2 m. PMID 37622681.

Certainty: Moderate · Provisional. Randomized trial measuring symptom and function outcomes, not hospitalizations or deaths. No heart-failure indication is approved.

Oral formulation cardiovascular safety. PIONEER 6 tested oral semaglutide 14 mg daily versus placebo in 3,183 adults with type 2 diabetes at high cardiovascular risk. It found noninferior cardiovascular safety. PMID 31185157.

Certainty: Moderate · Provisional. Event-driven safety trial, not powered for superiority.

Before human trials, semaglutide's development included medicinal-chemistry and toxicology work.

Lau et al. (2015) describes the structural engineering behind semaglutide, including the albumin-binding side chain and DPP-4-resistant substitutions that produced once-weekly dosing. PMID 26308095.

The most consequential animal finding involves the thyroid.

GLP-1 receptor agonists, including semaglutide, caused thyroid C-cell tumors, including adenomas and carcinomas, in lifetime rodent studies. Human relevance is unknown.

Rodent and human thyroid C-cells differ in GLP-1 receptor expression. Even so, the animal finding is the direct basis for the boxed warning in the US prescribing information.

No animal result is used here to claim a human benefit.

Semaglutide mimics GLP-1, a hormone released by the gut after meals.

In people, GLP-1 signaling has several documented effects.

• First, it prompts insulin release when blood sugar is high and suppresses glucagon, a hormone that raises blood sugar. These effects are glucose-dependent, meaning they fade as blood sugar normalizes.
• Second, it slows stomach emptying. This is part of why nausea is common.
• Third, it acts on brain circuits involved in appetite and food intake, reducing hunger and food preference.

These mechanisms are demonstrated in human pharmacology and are the standard explanation in the trial literature (Wilding et al., 2021 PMID 33567185).

Plausibility vs. demonstrated outcomes. The cardiovascular benefit in SELECT appeared partly independent of the amount of weight lost. The trial team reported that early weight change did not predict later cardiovascular outcomes.

That suggests mechanisms beyond weight loss may contribute. But the exact mechanism of cardiovascular risk reduction "has not been established" (Novo Nordisk, FDA label-expansion announcement, March 2024).

Researchers are investigating plausible contributors, including blood-pressure lowering, anti-inflammatory effects, and direct vascular effects. None is a demonstrated mechanism of the outcome benefit. Do not treat any of these as proven.

What trials observed. Gastrointestinal events are the signature side effect. These include nausea, vomiting, diarrhea, and constipation.

Most were mild-to-moderate and transient, but they led to more discontinuations with semaglutide. In STEP 1, discontinuations were 7.0% versus 3.1%.

In SELECT, adverse events leading to permanent discontinuation occurred in 16.6% versus 8.2%. Gallbladder-related disorders were also slightly more common, at 2.8% versus 2.3%. PMID 37952131.

Pancreatitis, meaning inflammation of the pancreas, is a labeled warning across the class based on postmarketing reports.

In September 2023, the FDA added ileus, or intestinal blockage, to the Ozempic label after postmarketing reports. The label notes that voluntary reports cannot reliably establish frequency or causality.

Boxed warning (rodents, not humans). US prescribing information carries a boxed warning because semaglutide caused thyroid C-cell tumors, including adenomas and carcinomas, in lifetime mouse and rat studies.

Human relevance is unknown.

The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Retinopathy signal. SUSTAIN 6 reported more retinopathy complications, meaning eye-related complications of diabetes, with semaglutide than placebo. Investigators associated the finding with rapid improvement in blood sugar.

This is a studied population-specific observation, not a general conclusion.

Suicidal thoughts. Case reports prompted regulatory investigation.

In January 2024, the FDA said its preliminary review of adverse-event reports found no causal link between GLP-1 drugs and suicidal thoughts. It also noted that it could not definitively exclude a small risk.

In April 2024, the EMA concluded that its review did not support a causal association. Monitoring continues.

Unanswered questions:

• Long-term effects beyond the about 2–4 year trial horizons are unstudied.
• Pregnant and breastfeeding people were excluded from these trials.
• The trials' participants were predominantly white, limiting generalizability.

Weight maintenance after stopping appears to require continued treatment. In the STEP 1 extension, two-thirds of lost weight was regained within a year. PMID 35441470.

We did not find reliable interaction data in the sources reviewed. That does not mean there are no interactions.

The label warns of higher hypoglycemia risk when semaglutide is combined with insulin or insulin secretagogues, meaning drugs that push insulin release.

Populations. Adults.

• STEP trials included people with BMI ≥30, or ≥27 with at least one weight-related condition such as hypertension or dyslipidemia, without diabetes.
• SELECT included people aged ≥45 with BMI ≥27 and established cardiovascular disease but no diabetes, across 41 countries.
• SUSTAIN 6, PIONEER 6, and FLOW included people with type 2 diabetes, with high cardiovascular risk or chronic kidney disease.
• HFpEF trials included people with obesity plus heart failure with preserved ejection fraction.
• Pediatric, pregnant, and breastfeeding populations were not studied in these trials.

Duration.

• Trial durations ranged from 26 weeks in PIONEER 1 to 104 weeks in SUSTAIN 6 and STEP 5.
• SELECT had a mean follow-up of 39.8 months, about 3.3 years.
• The STEP 1 extension followed participants to week 120 after stopping treatment.

Formulations and routes. Researchers studied once-weekly subcutaneous injection using Ozempic/Wegovy formulations and once-daily oral tablets using Rybelsus formulations. OASIS 1 studied a higher-dose oral tablet at 50 mg daily.

Injection and oral forms are different formulations with different doses and absorption. Results do not transfer between them.

Doses as historical context only. The following describes what researchers administered in trials. It is not a recommendation or protocol.

STEP/SELECT used semaglutide 2.4 mg weekly after about a 16-week dose-escalation period. Ozempic diabetes trials used 0.5, 1.0, and later 2.0 mg weekly. FLOW used 1.0 mg weekly. PIONEER used oral 3, 7, or 14 mg daily. OASIS 1 used oral 50 mg daily.

Every trial paired treatment with lifestyle intervention, meaning diet and activity counseling, and/or standard cardiovascular care.

No dose listed here is a protocol for anyone to follow.

United States. Ozempic: FDA-approved December 5, 2017 for type 2 diabetes; cardiovascular risk-reduction indication added January 2020 (based on SUSTAIN 6).

Rybelsus: FDA-approved September 20, 2019 for type 2 diabetes (oral).

Wegovy: FDA-approved June 4, 2021 for chronic weight management (2.4 mg weekly); cardiovascular indication added March 8, 2024 (based on SELECT), the FDA's first approval of a weight-management medicine for this cardiovascular use.

All are prescription-only.

Unapproved or compounded products sold under these names are not the approved products. The FDA has warned about unapproved GLP-1 products marketed for weight loss (FDA).

Canada. Ozempic: Health Canada authorized January 4, 2018 for type 2 diabetes.

Rybelsus: authorized March 30, 2020 for type 2 diabetes (Health Canada mid-year 2020 approvals update; PMPRB lists NOC date 30-Mar-20).

Wegovy: Health Canada has authorized it for chronic weight management. It launched in Canada in May 2024 (trade-press report; no manufacturer launch announcement located).

All are prescription-only.

Canadian market reports note Health Canada authorized generic semaglutide injection products in spring 2026, with the first NOCs in late April 2026, starting with type 2 diabetes indications. Authorization details are evolving and should be checked against the current Drug Product Database.

Health Canada has advised the public to think twice before injecting peptides bought online, noting unauthorized products and the research-use label problem (Health Canada advisory).

Other countries. Reviewed coverage for this profile is US + Canada only. The country selector on the live site will show this limitation. We do not claim worldwide status.

Authorization applies to specific products, formulations, indications, and countries.

A vendor shipping to your country is not the same as the product being authorized there.

No verification reports have been reviewed for this profile.

Straight Up Peptides has not purchased or commissioned testing of any semaglutide sample as of the literature-search date. There is therefore no independent testing badge and no sample report to inspect.

For context, a typical certificate of analysis (COA) can report the identity and analytical purity of the specific sample tested using methods such as HPLC or mass spectrometry.

A COA cannot establish:

• sterility
• endotoxin levels
• accurate fill mass per vial
• clinical safety
• regulatory authorization

A report describes the sample tested, not every batch from that vendor, and not the product category.

For approved brands, identity and quality are governed by regulated manufacturing and the approved label, not by third-party COAs.

For research-use or gray-market semaglutide sold online, the FDA's unapproved-product warnings (FDA) apply. Identity and purity claims on such products are not verified by any regulator.

Comparisons here are made at the level of matched research questions.

Different drugs were tested in different populations. Indirect comparisons across trials cannot substitute for head-to-head evidence.

Tirzepatide (dual GIP/GLP-1 receptor agonist). Tirzepatide was tested for weight management in SURMOUNT-1 (Jastreboff et al., NEJM 2022 PMID 35658024) and for diabetes in the SURPASS program.

It targets two receptors rather than one.

No large cardiovascular-outcomes trial of tirzepatide in obesity without diabetes was in our reviewed sources, so MACE conclusions are not comparable with SELECT.

Important difference: different molecule, different evidence base. Any efficacy comparison between trials is indirect.

Liraglutide (daily GLP-1 receptor agonist). The one direct head-to-head trial in our sources is STEP 8.

STEP 8 compared once-weekly semaglutide 2.4 mg with once-daily liraglutide 3.0 mg in adults with overweight or obesity (JAMA 2022 PMID 35015037).

Important difference: injection frequency, weekly versus daily, and trial-era evidence. This is the most comparable evidence available between the two.

Oral vs injectable semaglutide. These are different formulations, with different doses, studied in different populations and indications.

PIONEER, which studied oral semaglutide in diabetes, and STEP, which studied injectable semaglutide in obesity, do not produce results that automatically transfer between routes.

Compounded or research-use semaglutide. These products are not comparable to the approved brands. There are no reviewed trials, no reviewed quality data, and they are subject to the FDA's unapproved-product warnings.

No compound is ranked or badged as the winner. Missing evidence stays visible.

Is Ozempic the same thing as Wegovy?

They contain the same molecule, semaglutide, but they are different approved products. They use different doses and delivery devices, have different approved indications, and were studied in different trial programs.

Approval of one does not cover the other.

Do the trials show it works without diet and exercise changes?

No.

Every major trial paired semaglutide with lifestyle intervention, including diet and activity counseling, and, where relevant, standard cardiovascular care.

The trial results describe the combination studied, not the drug alone.

If I stop taking it, does the weight stay off?

The STEP 1 extension suggests not, on average.

One year after stopping semaglutide 2.4 mg weekly and stopping the lifestyle program, participants had regained about two-thirds of the weight they had lost. Cardiometabolic improvements mostly moved back toward baseline. PMID 35441470.

This was an exploratory analysis in 327 participants. The direction is clear, but it is not a precise prediction for any individual.

Is it approved for heart failure?

No.

STEP-HFpEF showed improvements in heart-failure symptoms, physical limitations, and walking distance versus placebo. PMID 37622681.

But the trial was not designed around hospitalizations or deaths, and no heart-failure indication has been approved.

Symptom improvement in a trial is not the same as an approved indication.

Does the thyroid warning mean it causes thyroid cancer in people?

The boxed warning comes from rodent studies. Human relevance is unknown.

The reviewed trials were not designed to assess human thyroid cancer risk.

This is an open question, not a confirmed human risk, and not reassurance either.

Are the generic versions the same?

In Canada, generic semaglutide injection products received Health Canada authorization starting April 2026 for type 2 diabetes indications, per market reports.

A generic is authorized against its own reviewed submission. Check the current Drug Product Database for the specific product and indication rather than assuming interchangeability with every brand and use.

Reviewed references

All verified against PubMed; PMIDs link to pubmed.ncbi.nlm.nih.gov.

Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–80. PMID 26308095. DOI: 10.1021/acs.jmedchem.5b00726 Structural design and pharmacology (preclinical/chemistry).

Marso SP et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44. PMID 27633186. DOI: 10.1056/NEJMoa1607141 Human RCT, n=3,297. ClinicalTrials.gov NCT01720446.

Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42:1724–32. PMID 31186300. DOI: 10.2337/dc19-0749 Human RCT, n=703.

Husain M et al.; PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381:841–51. PMID 31185157. DOI: 10.1056/NEJMoa1901118 Human RCT, n=3,183.

Wilding JPH et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. PMID 33567185. DOI: 10.1056/NEJMoa2032183 Human RCT, n=1,961. ClinicalTrials.gov NCT03548935.

Wilding JPH et al.; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID 35441470. DOI: 10.1111/dom.14725 Human RCT extension, n=327 (exploratory).

Garvey WT et al.; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083–91. PMID 36216945. DOI: 10.1038/s41591-022-02026-4 Human RCT, n=304. ClinicalTrials.gov NCT03693430.

Rubino DM et al.; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022;327(2):138–50. PMID 35015037. DOI: 10.1001/jama.2021.23619 Human RCT (head-to-head semaglutide vs liraglutide).

Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402:705–19. PMID 37385278. Human RCT.

Kosiborod MN et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389:1069–84. PMID 37622681. DOI: 10.1056/NEJMoa2306963 Human RCT, about 529 participants. ClinicalTrials.gov NCT04788511.

Lincoff AM et al.; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221–32. PMID 37952131. DOI: 10.1056/NEJMoa2307563 Human RCT, n=17,604.

Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024. DOI: 10.1038/s41591-024-02996-7 Prespecified SELECT analysis (weight at 208 weeks).

Perkovic V et al.; FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109–21. PMID 38785209. DOI: 10.1056/NEJMoa2403347 Human RCT (stopped early).

Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–16. PMID 35658024. DOI: 10.1056/NEJMoa2206038 Human RCT (comparator compound, cited in the comparison section only).

Regulatory sources

FDA press release, "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight," March 8, 2024.

FDA-approved prescribing information for Ozempic/Wegovy/Rybelsus (boxed warning: thyroid C-cell tumors in rodents; ileus added to Ozempic label September 2023; pancreatitis warnings).

FDA statement on GLP-1 drugs and suicidal thoughts, January 2024 (preliminary FAERS review: no causal link found; monitoring continues).

EMA PRAC review, April 2024 (no causal association with suicidal ideation).

Novo Nordisk press releases: Ozempic US approval December 2017; Ozempic CV risk-reduction indication January 2020; Wegovy US approval June 4, 2021; Ozempic Health Canada authorization January 4, 2018.

FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (Dec 2023, updated June 15, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (URL returned 404 on 2026-10-06; the FDA appears to have moved the page after its June 2026 update).

Methodology

Literature search: PubMed (title/abstract and MeSH searches for "semaglutide" combined with trial-program terms), ClinicalTrials.gov (NCT01720446, NCT03548935, NCT03693430, NCT04788511), FDA press announcements and approved labeling, and secondary trial summaries used only to locate primary figures.

Inclusion: published, peer-reviewed human randomized trials and the key medicinal-chemistry paper; regulatory actions from official sources.

Exclusion: conference abstracts without full publication, observational studies (not needed given the RCT base), and marketing materials.

Every material conclusion above traces to a cited reference. Numeric results are reported as published. Trial summaries were cross-checked against abstracts where full text was paywalled.

Manufacturer funding (Novo Nordisk) is disclosed for the trial programs. It is a limitation, not a disqualification.

Contributors

Written by the Evidence Research Team, a collective editorial byline. No individual credentials are claimed.

Scientific reviewer: not yet assigned (this profile is a draft; scientific review is pending).

Publishing editor: not yet assigned (editorial review is pending).

No external funding was involved in this profile.

Dates

Literature-search date: 2026-10-05.

Profile drafted: 2026-10-05.

Scientific review date: pending (draft, not yet scientifically reviewed).

Scheduled reassessment: set once published, per the site's review cadence.

Corrections

Spotted something we should check? Send us the source: /corrections/.

Substantive changes will be logged here with dates. Cosmetic edits will not reset the review date.